SecBot SecBot
DEFA14A ·Filed Aug 28, 2026

CSBR

CHAMPIONS ONCOLOGY, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago SEC0001628280-26-059374
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine notice of proxy availability with no new financial information. Monitor the definitive proxy statement for details on the 2026 Equity Incentive Plan, which could involve future dilution. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
CSBR ▲ 0.00% at T+20d
NEUTRAL call 0.00% · α vs SPY -0.26% · entry $4.93 → $4.93
Next anchor: T+60d in 27d
Latest observation: T+39 +9.29% FF3 residual α
Entry = T+0 close
Aug 28, 2026
via day close
T+1d
+1.32%
call +1.32% · α +1.62%
$5.00
settled 8w ago
T+5d
+5.88%
call +5.88% · α +5.77%
$5.22
settled 8w ago
T+20d
0.00%
call 0.00% · α -0.26%
$4.93
settled 29d ago
T+60d
Pending
in 27d

Price Chart

Loading chart...

Executive Summary

Champions Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2026 annual meeting. The meeting will include election of seven directors, ratification of EisnerAmper as auditor, an advisory vote on executive compensation, and approval of a new 2026 Equity Incentive Plan. The board recommends a 'for' vote on all proposals. This is a routine administrative filing with no material financial impact.

Key Financial Metrics

Vote
director election
Meeting
2026-10-14
Seats Contested
7

Key Facts

  • Annual meeting scheduled for October 14, 2026 at 9:00 a.m. local time in Hackensack, NJ
  • Record date for voting is August 21, 2026
  • Proposals include election of 7 directors, ratification of EisnerAmper LLP, advisory vote on executive compensation, and approval of 2026 Equity Incentive Plan
  • Board recommends voting FOR all proposals
  • Notice of internet availability of proxy materials — not a proxy card

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-059374
Document: 0001628280-26-059374-index-headers.html0001628280-26-059374
Document: 0001628280-26-059374-index.html0001628280-26-059374
Document: 0001628280-26-059374.txt0001628280-26-059374
2 reports for CSBR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CSBR — sortable, filterable
TypeNow
Sep 10, 2026
6w ago
8-K
BULLISH ★ 6/10
$5.10 $4.84▼ −5.10%▼ −6.97%$4.72 (−7.45%)
Aug 28, 2026
8w ago
DEFA14A
NEUTRAL ★ 2/10
$4.93 $4.93· 0.00%▼ −0.26%$4.72 (−4.26%)
Showing 2 of 2

US Market Status

Market Closed — Opens Wed (13h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026